Exelixis Inc (EXEL)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 33% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+47% over the past year+3
- 52-week positionIn the upper quarter of its 52-week range+18
- QualityStrong net margin (35%)+7
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst here is earnings, driven by CABOMETYX revenue strength, with a secondary regulatory overhang from the zanzalintinib FDA delay and competitive noise from Merck's expanded Welireg label. Given the mixed signals, the probability that the move continues over the next few weeks is roughly 40–50%, framed as modestly uncertain rather than a strong trend. Informational only — not financial advice.
- Exelixis Shares Rising on CABOMETYX RevenueYahoo · 2026-09-30
- FDA Expands Merck's Welireg Label for a New Kidney Cancer IndicationYahoo · 2026-09-28
- Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?Yahoo · 2026-09-24
- Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?Yahoo · 2026-09-22
- Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal CancerYahoo · 2026-09-21
Any AI summary is an interpretation of public news, not advice or a price target.